Heart-Focused Biotech Closes $260M Series B Funding Round
By Jade Martinez-Pogue · July 16, 2024, 5:06 PM EDT
Clinical-stage biotechnology company Cardurion Pharmaceuticals Inc. on Tuesday announced that it has raised $260 million in Series B financing that will go toward helping the Burlington, Massachusetts-based company continue developing therapies...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login